Skip to main content
. 2013 Sep 20;98(12):4899–4907. doi: 10.1210/jc.2013-2373

Table 3.

OR (95% CI) by Multiple Logistic Regression Models for Metabolic Syndrome Components in Relation to Biomarkersa

Irisin (n = 148)
Adiponectin (n = 146)
T1, n = 49 T2, n = 50 T3, n = 49 P for Trend T1, n = 48 T2, n = 49 T3, n = 49 P for Trend
MetS, n 5/49 13/50 25/49 25/48 13/49 5/49
    Model 1 1 3.09 (1.01–9.48) 9.17 (3.11–27.0) <.001 1 0.33 (0.14–0.78) 0.11 (0.04–0.31) <.001
    Model 2 1 2.69 (0.84–8.59) 9.80 (3.12–30.8) <.001 1 0.26 (0.10–0.68) 0.07 (0.02–0.24) <.001
    Model 3 1 2.46 (0.67–9.02) 12.43 (3.42–45.2) <.001 1 0.28 (0.10–0.78) 0.07 (0.02–0.28) <.001
WC,b n 23/49 30/50 33/49 33/48 28/49 24/49
    Model 1 1 1.70 (0.76–3.76) 2.33 (1.03–5.29) .04 1 0.61 (0.26–1.39) 0.44 (0.19–0.999) .05
    Model 2 1 1.16 (0.68–4.06) 2.78 (1.11–6.99) .03 1 0.42 (0.16–1.11) 0.21 (0.07–0.59) .003
    Model 3 1 2.64 (0.28–24.5) 1.99 (0.22–17.7) .58 1 0.54 (0.06–4.57) 0.27 (0.03–2.53) .25
BP,c n 18/49 25/50 29/49 23/48 31/49 18/49
    Model 1 1 1.77 (0.77–3.84) 2.50 (1.11–5.63) .03 1 1.87 (0.83–4.21) 0.63 (0.28–1.42) .80
    Model 2 1 1.49 (0.59–3.72) 3.15 (1.21–8.22) .02 1 2.16 (0.84–5.58) 0.44 (0.16–1.21) .12
    Model 3 1 1.31 (0.47–3.63) 2.51 (0.91–6.88) .07 1 3.12 (1.10–8.85) 0.70 (0.22–2.21) .59
Glucose,d n 5/49 9/50 18/49 16/48 11/49 5/49
    Model 1 1 1.93 (0.60–6.24) 5.11 (1.71–15.2) .002 1 0.58 (0.24–1.42) 0.23 (0.08–0.69) .007
    Model 2 1 2.12 (0.62–7.28) 6.04 (1.87–19.5) .002 1 0.58 (0.22–1.52) 0.22 (0.07–0.71) .01
    Model 3 1 1.80 (0.50–6.46) 5.80 (1.72–19.6) .003 1 0.65 (0.24–1.77) 0.28 (0.08–0.95) .04
TG,e n 8/49 10/50 19/49 17/48 14/49 6/49
    Model 1 1 1.28 (0.46–3.58) 3.25 (1.25–8.4) .001 1 0.73 (0.31–1.72) 0.25 (0.09–0.72) .01
    Model 2 1 1.19 (0.35–4.04) 4.23 (1.31–13.7) .01 1 0.52 (0.18–1.48) 0.14 (0.04–0.55) .005
    Model 3 1 0.97 (0.27–3.24) 3.89 (1.16–13.0) .02 1 0.55 (0.19–1.63) 0.18 (0.04–0.73) .02
HDL,f n 9/49 18/50 23/49 26/48 14/49 8/49
    Model 1 1 2.5 (0.99–6.31) 3.93 (1.57–9.82) .003 1 0.34 (0.15–0.78) 0.17 (0.06–0.43) <.001
    Model 2 1 2.96 (1.09–8.0) 4.82 (1.79–13.0) .002 1 0.19 (0.07–0.50) 0.07 (0.02–0.24) <.001
    Model 3 1 2.75 (1.002–7.54) 4.56 (1.68–12.4) .003 1 0.19 (0.07–0.53) 0.08 (0.02–0.27) <.001
a

Model 1 is unadjusted. Model 2 is adjusted for age, gender, race, smoking status, physical activity, vegetable or fruit consumption, and alcohol consumption. Model 3 is adjusted as for model 2 plus BMI. Tertile values of biomarkers are expressed as T1, T2, and T3. (For irisin [nanograms per milliliter]: T1, 72.19–157.09; T2, 157.1–209.00; T3, 209.01–749.34; and for adiponectin [micrograms per milliliter]: T1, 1.12–5.60; T2, 5.61–10.6; T3, 10.7–28.8).

b

WC ≥102 cm for men and ≥88 cm for women.

c

Systemic hypertension (BP ≥130/85 mm Hg) or antihypertensive therapy.

d

Elevated FPG (≥100 mg/dL) or history of diabetes mellitus or taking antidiabetic medications.

e

Elevated TG (≥150 mg/dL) or specific medication for elevated TG.

f

Low HDL-cholesterol (men, <40 mg/dL; women, <50 mg/dL) or specific medication for low HDL.

HHS Vulnerability Disclosure